TB-500 vs Full TB4
Last updated: March 2026
TB-500 is a synthetic fragment — amino acids 17-23 of a 43-amino-acid protein. Full thymosin beta-4 is that complete protein. Does the fragment deliver the same results? Here's what the research actually shows.
TB-500 reproduces the actin-binding domain (amino acids 17-23) of full thymosin beta-4. Full TB4 binds actin and promotes cell migration in published research, and one mouse study found the 17-23 peptide promoted skin-wound repair (Philp 2003), but no source on this page shows that this region drives full TB4's other repair effects. Most published research on angiogenesis, inflammation and cardiac repair used the full protein — whether the fragment alone reproduces those effects is largely untested. Is the fragment good enough? Or are you leaving significant biology on the table?
(TB-500 Fragment)
(Full TB4)
(TB-500 Fragment)
Fragment vs Complete Peptide
Understanding the structural difference is essential to understanding the difference in effects. This isn't a minor formulation variant — it's a fundamentally different molecular entity: 7 amino acids versus 43.
A synthetic peptide reproducing amino acids 17 through 23 (LKKTETQ) of the mature thymosin beta-4 sequence. Philp et al. (2003) describe this seven-amino-acid synthetic peptide as containing the actin-binding domain of thymosin beta-4 and report that it promoted dermal wound repair in aged mice comparably to the full protein (PMID 12581423). Beyond that, whether the fragment alone drives cell migration or repair has largely not been tested. Small molecular weight. Easier to synthesize correctly due to shorter sequence. Its direct evidence base is small: most published thymosin beta-4 studies used the full peptide.
The complete 43-amino-acid peptide. Originally thought to be a thymic hormone, it is present in high concentrations in almost every cell as the main intracellular G-actin-sequestering peptide, and is also detected in blood plasma and wound fluid (Huff et al., 2001). After injury it is released by platelets, macrophages and many other cell types (Goldstein et al., 2012). Contains the actin-binding region (positions 17-23) plus the rest of the sequence. One N-terminal fragment outside that region, Ac-SDKP, has reported effects of its own (inhibition of bone marrow stem cell proliferation) (Huff et al., 2001); how the rest of the sequence contributes to TB4's tissue-repair effects has largely not been mapped.
Complete Comparison Table
| Feature | 💧 TB-500 | 🧬 Full Thymosin Beta-4 |
|---|---|---|
| Structure | 7 amino acids (fragment, AA 17–23) | 43 amino acids (complete protein) |
| Origin | Synthetic reproduction of actin-binding domain | Originally thought to be a thymic hormone; present in almost every cell |
| Molecular Weight | ~889 Daltons (calculated from sequence) | ~4,900 Daltons |
| Primary Mechanism | Proposed: actin binding → cell migration (largely untested for the fragment) | Actin sequestration + broader effects reported in preclinical research |
| Angiogenesis | Limited fragment-specific data | Broader preclinical evidence (rodents) |
| Inflammation | Limited fragment-specific data | Reduced inflammatory cytokine and chemokine mRNA after corneal injury (mice) |
| Tissue Remodeling | Limited fragment-specific data | Fewer myofibroblasts, reduced scar formation (review) |
| Cardioprotection | Not tested in our sources | Reported — improved early myocyte survival and cardiac function post-MI (mice) |
| Neural Repair | No data in our sources | Proposed CNS repair after ischemia/trauma (review) |
| Stem Cell Mobilization | Not tested | Reported stem/progenitor cell mobilization & differentiation (review) |
| Human Clinical Trials | None | Yes — phase 1 cardiovascular trials and wound-repair trials reported |
| FDA Status | Not approved, unregulated research peptide | Not approved |
| WADA Status | Prohibited — confirm on the current WADA Prohibited List | Prohibited — confirm on the current WADA Prohibited List |
| Availability | Wide — most research suppliers carry it | Limited — fewer suppliers, harder to source |
| Typical Cost | Lower — prices vary by vendor | Higher — prices vary by vendor |
| Synthesis Complexity | Simpler (7 AA) | More complex (43 AA) — quality variance higher |
| Common Stack Partners | BPC-157, GHK-Cu | BPC-157, GHK-Cu (combinations untested) |
Shared Pathways vs TB4's Additional Biology
Both peptides contain the actin-binding region. But most research on broader effects used the complete protein — whether the fragment replicates them is largely untested.
TB-500 contains the actin-binding region of TB4, but fragment-specific studies are limited — one mouse study (Philp et al., 2003) found the isolated fragment promoted dermal wound repair in aged mice comparably to full TB4; most other effects are documented only for full TB4. What it doesn't have: the rest of the 43-amino-acid sequence, whose contribution to TB4's broader effects has not been mapped.
- Contains the actin-binding sequence (fragment-specific data limited)
- Dermal wound repair in aged mice comparable to full TB4 (one study, PMID 12581423); cell migration otherwise largely untested for the fragment
The complete protein contains the TB-500 sequence plus the rest of the chain. Preclinical studies of the full peptide report the effects below; which parts of the sequence drive them — and whether the fragment shares them — is largely untested. A 2001 review said the molecular mechanism of extracellular thymosin beta-4 was not known (Huff et al., 2001); a later mouse and cell study linked full TB4 to a PINCH–ILK complex that activates the survival kinase Akt (Bock-Marquette et al., 2004).
- Contains the TB-500 sequence, plus reported:
- Angiogenesis and wound repair in normal and aged rodents (Philp 2004)
- Reduced inflammatory cytokine and chemokine mRNA after corneal alkali injury in mice (Sosne 2002)
- Epicardial cells migrating and differentiating into endothelial and smooth-muscle cells (Smart 2007)
- PINCH/ILK complex → Akt activation, improved myocyte survival post-MI in mice (Bock-Marquette 2004)
- Fewer myofibroblasts and reduced scar formation in wounds (Goldstein 2012 review)
- Proposed repair of heart and CNS tissue after ischemia and trauma (Goldstein 2012 review)
- Stem/progenitor cell mobilization and differentiation (Goldstein 2012 review)
Where Full TB4 Has the Evidence
Based on published preclinical and clinical research. Bars are our editorial read of how much evidence the cited sources give each peptide — not measured effect sizes. The two were never compared head-to-head, so this shows where data exist, not which works better.
The Research Gap — and Why It Matters
Here's the critical point that most TB-500 guides gloss over: most published studies on thymosin beta-4 were done on the FULL peptide, not the fragment. TB-500's evidence base is significantly smaller than commonly cited.
One review notes that increased beta-thymosin expression might promote metastasis, possibly by increasing the mobility of cells (Huff et al., 2001). Whether TB4 or TB-500 use affects cancer risk in people is not established by the sources on this page. This remains an active area of research with incomplete data. As a precaution, individuals with active cancer, personal history of malignancy, or strong family history should avoid thymosin beta-4 compounds until more robust safety data is available. This is a flag, not a confirmed risk — but a flag worth taking seriously.
When to Choose TB-500 vs Full TB4
Neither is "better" universally. The right choice depends on your goal, injury type, budget, and risk tolerance.
- Acute soft-tissue injuries (tendons, ligaments, muscle) are a common community use — no source on this page tests TB-500 on these injuries
- Budget-conscious protocols — typically cheaper than full TB4
- First-time users who want the cheaper, easier-to-source option (note: the fragment itself is less studied than full TB4)
- Widely available from research suppliers — more vendor options, more competition on quality
- Chronic injuries — some users anecdotally report trying full TB4 here; no study has compared the two
- Interest in cardiac research — the cardiac data (mice) used full TB4; fragment-specific data is lacking
- Interest in neural-repair research (proposed only)
- Building a stack with BPC-157 + GHK-Cu around the molecule used in most published research
- Research context where you want full biological equivalence to published TB4 studies
Building the Recovery Stack
Both TB-500 and full TB4 are commonly discussed alongside BPC-157 and GHK-Cu. They are proposed to act through different pathways, but none of these combinations — or BPC-157 and GHK-Cu themselves — is tested in the sources on this page.
The most discussed healing combo in the research community. The two are proposed to act through different mechanisms; neither BPC-157's mechanisms nor the combination's safety is tested in the sources on this page.
Full TB4 is the molecule used in most published preclinical research, including cardiac and anti-inflammatory work the fragment has largely not been tested in. Some users anecdotally report stronger results in chronic injuries; no study has compared the two.
Adds GHK-Cu (copper peptide), which is commonly discussed alongside these two. None of the sources on this page tests GHK-Cu or this three-peptide combination. Cost and complexity increase.
The Practical Reality
Even if full TB4 is theoretically superior for certain applications, the practical gap in availability and cost is real. Quality matters more with full TB4 due to synthesis complexity.
Quality matters more with full TB4: A 43-amino-acid peptide has far more opportunities for synthesis errors, truncations, and impurities than a 7-amino-acid fragment. If you're paying the premium for full TB4, using a low-quality, unverified product defeats the purpose. Look for suppliers who provide third-party LCMS mass spectrometry certificates (not just HPLC purity). The cost difference between a verified-quality TB4 vial and a cheap unverified one is small compared to the cost of injecting a substandard product.
Common Questions Answered
Sources & References
The Bottom Line
- TB-500 is a fragment (7 AA); full TB4 is the complete 43-AA protein — structurally distinct
- Both contain the actin-binding region; evidence for broader effects comes from the full peptide, and the fragment has largely not been tested for them
- Full TB4 has entered human trials (phase 1 cardiovascular trials reported by Smart 2007; RegeneRx's RGN-259 dry-eye program is not covered by our PubMed sources); no human trial of TB-500 is cited here
- Cardiac and anti-inflammatory evidence comes from full-TB4 research, mostly in animals
- TB-500 is cheaper and widely available, but its soft-tissue use rests on community reports — the only fragment study cited here is in mouse skin wounds, not tendon, ligament or muscle
- BPC-157 + TB-500 is the most commonly discussed healing stack — the combination has not been clinically tested
- Neither is FDA-approved — both are sold as research chemicals only
- Study counts cited for TB-500 are misleading — most research is on full TB4, not the fragment
- Full TB4 synthesis is complex (43 AA); quality variance across suppliers is higher
- Both are listed as prohibited in sport — tested athletes should confirm on the current WADA Prohibited List
- Whether TB4 affects cancer risk is an open research question — precautionary caution warranted
- Full TB4 availability is more limited; verify quality with LCMS testing before use
- Long-term safety data in humans is essentially nonexistent for both compounds
🔬 Research Supplier
Research compounds from Swiss Chems, which publishes vendor COAs for selected products.
Affiliate links — support HighPeptides at no extra cost. Swiss Chems publishes third-party HPLC COAs for selected products — vendor-published, a claim to verify. HPLC shows purity, not the LCMS identity check recommended above.
Peptide Reconstitution Supplies
Everything you need to safely reconstitute and inject research peptides.
Affiliate links — support HighPeptides at no extra cost.
Continue Reading
Research-Grade Peptides
Swiss Chems publishes third-party COAs for selected products — vendor-published, a claim to verify.
Browse Swiss Chems →Affiliate links — support HighPeptides at no extra cost.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place. For TB-500 and full TB4, no human study has established a dose or cycle length.
Get the Guide — $19 (normally $29) →
New to peptides? Start with the $19 Buyer’s Playbook →
This page is for educational and informational purposes only. It is not medical advice. Neither TB-500 nor thymosin beta-4 is FDA-approved for human use. Both are sold as research chemicals only. Both are listed as prohibited on the WADA Prohibited List. Most published research is preclinical (animal studies) — human trials of thymosin beta-4 have included RegeneRx's ophthalmic eye drop formulation (RGN-259) and reported phase 1 cardiovascular and wound-repair trials. No doses are given on this page; community protocols mentioned are not clinical or FDA-approved recommendations. Research peptide purity and identity are not guaranteed by vendors — third-party testing is essential, especially for full thymosin beta-4. Always consult a qualified healthcare provider. HighPeptides does not sell peptides or endorse their use outside of legitimate research settings.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars — metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.